Novobiocin Attacks BRCA-Mutated Cancer Cells from Within and

As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells.

Related Keywords

Dana Farber Cancer Institute , Massachusetts , United States , Boston , Benz Stanger , Geoffrey Shapiro , Gerburgm Wulf , Anitak Mehta , Andrewj Aguirre , Constantia Pantelidou , Brianm Wolpin , Jamesm Cleary , Jenniferl Guerriero , Aland Dandrea , Carter Grochala , Heta Jadhav , Jeffrey Patterson Fortin , Ludwig Center At Harvard , University Of Pennsylvania School Medicine , National Institutes Of Health , Blood Disorders Center , Smith Family Foundation , Beth Israel Deaconess Medical Center , Cancer Center , Breast Cancer Research Foundation , Harvard Medical School , Nature Communications , Fanconi Anemia Research Fund , Drug Administration , Dana Farber Brigham Cancer Center , Tin Phan , Pennsylvania School , National Institutes , Harvard Cancer Center Specialized Program , Research Excellence , Gastrointestinal Cancer , Cancer Pancreatic Challenge , Ludwig Center , Breast Cancer , Wong Family Award , Farber Cancer Institute , Comprehensive Cancer Center , Harvard Medical , Boston Children , Blood Disorders , World Report Best Cancer Hospital , Novobiocin , Patients With Cancers Carrying Brca Gene Mutations , D , Phd ,